<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38802702</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0973</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Infection</Title><ISOAbbreviation>Infection</ISOAbbreviation></Journal><ArticleTitle>The roles of the kynurenine pathway in COVID-19 neuropathogenesis.</ArticleTitle><Pagination><StartPage>2043</StartPage><EndPage>2059</EndPage><MedlinePgn>2043-2059</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s15010-024-02293-y</ELocationID><Abstract><AbstractText>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the highly contagious respiratory disease Corona Virus Disease 2019 (COVID-19) that may lead to various neurological and psychological disorders that can be acute, lasting days to weeks or months and possibly longer. The latter is known as long-COVID or more recently post-acute sequelae of COVID (PASC). During acute COVID-19 infection, a strong inflammatory response, known as the cytokine storm, occurs in some patients. The levels of interferon-&#x3b3; (IFN-&#x3b3;), interferon-&#x3b2; (IFN-&#x3b2;), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-&#x3b1;) are particularly increased. These cytokines are known to activate the enzyme indoleamine 2,3-dioxygenase 1 (IDO-1), catalysing the first step of tryptophan (Trp) catabolism through the kynurenine pathway (KP) leading to the production of several neurotoxic and immunosuppressive metabolites. There is already data showing elevation in KP metabolites both acutely and in PASC, especially regarding cognitive impairment. Thus, it is likely that KP involvement is significant in SARS-CoV-2 pathogenesis especially neurologically.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dehhaghi</LastName><ForeName>Mona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heydari</LastName><ForeName>Mostafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Science, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panahi</LastName><ForeName>Hamed Kazemi Shariat</ForeName><Initials>HKS</Initials><AffiliationInfo><Affiliation>Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewin</LastName><ForeName>Sharon R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Victorian Infectious Diseases Service, The Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, The Alfred Hospital and Monash University, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heng</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia. benjamin.heng@mq.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brew</LastName><ForeName>Bruce J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Peter Duncan Neurosciences Unit, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia. Bruce.Brew@svha.org.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, School of Clinical Medicine, UNSW Sydney, NSW, Australia. Bruce.Brew@svha.org.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Neurology and Immunology, St. Vincent's Hospital, Sydney, NSW, Australia. Bruce.Brew@svha.org.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Notre Dame, Darlinghurst, Sydney, NSW, Australia. Bruce.Brew@svha.org.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillemin</LastName><ForeName>Gilles J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Peter Duncan Neurosciences Unit, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Mathematics and Natural Sciences, Institut Pertanian Bogor University, Bogor, Indonesia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Macquarie University Research Excellence Scholarship</GrantID><Agency>Macquarie University</Agency><Country/></Grant><Grant><GrantID>APP1176660</GrantID><Agency>National Health and Medical Research Council</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Infection</MedlineTA><NlmUniqueID>0365307</NlmUniqueID><ISSNLinking>0300-8126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>343-65-7</RegistryNumber><NameOfSubstance UI="D007737">Kynurenine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050503">Indoleamine-Pyrrole 2,3,-Dioxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>8DUH1N11BX</RegistryNumber><NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007737" MajorTopicYN="Y">Kynurenine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050503" MajorTopicYN="N">Indoleamine-Pyrrole 2,3,-Dioxygenase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014364" MajorTopicYN="N">Tryptophan</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Kynurenine pathway</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Neurological manifestations</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Tryptophan</Keyword></KeywordList><CoiStatement>The authors have no relevant financial or non-financial interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>28</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>27</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38802702</ArticleId><ArticleId IdType="pmc">PMC11499433</ArticleId><ArticleId IdType="doi">10.1007/s15010-024-02293-y</ArticleId><ArticleId IdType="pii">10.1007/s15010-024-02293-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ng LF, Hiscox JA. Coronaviruses in animals and humans. BMJ. 2020. 10.1136/bmj.m634.</Citation><ArticleIdList><ArticleId IdType="pubmed">32075782</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz-Prado E, Simba&#xf1;a-Rivera K, G&#xf3;mez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, Muslin C, Jaramillo AMG, Barba-Ostria C, Cevallos-Robalino D. Clinical, molecular and epidemiological characterization of the SARS-CoV2 virus and the Coronavirus disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020;98: 115094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260568</ArticleId><ArticleId IdType="pubmed">32623267</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097006</ArticleId><ArticleId IdType="pubmed">30531947</ArticleId></ArticleIdList></Reference><Reference><Citation>Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020;25:278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169770</ArticleId><ArticleId IdType="pubmed">32052514</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining &#x2018;host jump&#x2019;of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. 2015;23:468&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125587</ArticleId><ArticleId IdType="pubmed">26206723</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020. 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian D, Ye Q. Hepatic complications of COVID-19 and its treatment. J Med Virol. 2020;92:1818&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280725</ArticleId><ArticleId IdType="pubmed">32437004</ArticleId></ArticleIdList></Reference><Reference><Citation>Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38:1504&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165109</ArticleId><ArticleId IdType="pubmed">32317203</ArticleId></ArticleIdList></Reference><Reference><Citation>Needham EJ, Chou SH-Y, Coles AJ, Menon DK. Neurological implications of COVID-19 infections. Neurocrit Care. 2020;32:667&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188454</ArticleId><ArticleId IdType="pubmed">32346843</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawler NG, Gray N, Kimhofer T, Boughton B, Gay M, Yang R, Morillon A-C, Chin S-T, Ryan M, Begum S. Systemic perturbations in amine and kynurenine metabolism associated with acute SARS-CoV-2 infection and inflammatory cytokine responses. J Proteome Res. 2021;20:2796&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">33724837</ArticleId></ArticleIdList></Reference><Reference><Citation>Quist-Paulsen E, Aukrust P, Kran A-MB, Dunlop O, Ormaasen V, Stiksrud B, Midttun &#xd8;, Ueland T, Ueland PM, Mollnes TE. High neopterin and IP-10 levels in cerebrospinal fluid are associated with neurotoxic tryptophan metabolites in acute central nervous system infections. J Neuroinflammation. 2018;15:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6260858</ArticleId><ArticleId IdType="pubmed">30470234</ArticleId></ArticleIdList></Reference><Reference><Citation>Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res. 2009;16:77&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">19526301</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillemin GJ. Quinolinic acid: neurotoxicity. FEBS J. 2012;279:1355&#x2013;1355.</Citation><ArticleIdList><ArticleId IdType="pubmed">22251552</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, Hudson KE, Zimring JC, Hansen KC, Hod EA. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI insight. 2020. 10.1172/jci.insight.140327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7453907</ArticleId><ArticleId IdType="pubmed">32559180</ArticleId></ArticleIdList></Reference><Reference><Citation>Cysique LA, Jakabek D, Bracken SG, Allen-Davidian Y, Heng B, Chow S, Dehhaghi M, Staats-Pires A, Darley DR, Byrne A, Phetsouphanh C, Kelleher A, Dore GJ, Matthews GV, Guillemin GJ, Brew BJ. Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study. Ann Clin Transl Neurol. 2022;10:1338&#x2013;52.</Citation></Reference><Reference><Citation>Fernstrom JD. Role of precursor availability in control of monoamine biosynthesis in brain. Physiol Rev. 1983;63:484&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">6132421</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh DM, Dougherty DM, Moeller FG, Swann AC, Spiga R. Laboratory-measured aggressive behavior of women: acute tryptophan depletion and augmentation. Neuropsychopharmacology. 2002;26:660.</Citation><ArticleIdList><ArticleId IdType="pubmed">11927191</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehhaghi M, Kazemi Shariat Panahi H, Guillemin GJ. Microorganisms, tryptophan metabolism, and kynurenine pathway: a complex interconnected loop influencing human health status. Int J Tryptophan Res. 2019;12:1178646919852996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6585246</ArticleId><ArticleId IdType="pubmed">31258331</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehhaghi M, Panahi HKS, Heng B, Guillemin GJ. The gut microbiota, kynurenine pathway, and immune system interaction in the development of brain cancer. Front Cell Dev Biol. 2020;19: 562812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7710763</ArticleId><ArticleId IdType="pubmed">33330446</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001;78:842&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520905</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: Tryptophan&#x2019;s metabolites in exercise, inflammation, and mental health. Science. 2017. 10.1126/science.aaf9794.</Citation><ArticleIdList><ArticleId IdType="pubmed">28751584</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone TW. Does kynurenic acid act on nicotinic receptors? An assessment of the evidence. J Neurochem. 2020;152:627&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7078985</ArticleId><ArticleId IdType="pubmed">31693759</ArticleId></ArticleIdList></Reference><Reference><Citation>Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478:197&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">21976023</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J. 2012;279:1356&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">22248144</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugo-Huitr&#xf3;n R, Ugalde Mu&#xf1;iz P, Pineda B, Pedraza-Chaverr&#xed; J, R&#xed;os C, P&#xe9;rez-de la Cruz V. Quinolinic acid: an endogenous neurotoxin with multiple targets. Oxidative med cell longev. 2013. 10.1155/2013/104024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3780648</ArticleId><ArticleId IdType="pubmed">24089628</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cruz VP D, Carrillo Mora P, Santamar&#xed;a A (2012) Quinolinic acid an endogenous molecule combining excitotoxicity oxidative stress and other toxic mechanisms. International Journal of Tryptophan Research. 5, IJTR-S8158</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3296489</ArticleId><ArticleId IdType="pubmed">22408367</ArticleId></ArticleIdList></Reference><Reference><Citation>Santamar&#xed;a A, Galv&#xe1;n-Arzate S, Lis&#xfd; V, Ali SF, Duhart HM, Osorio-Rico L, R&#xed;os C, Sut&#x2019;astn&#xfd; F. Quinolinic acid induces oxidative stress in rat brain synaptosomes. NeuroReport. 2001;12:871&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11277599</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwidzinski E, Bechmann I. IDO expression in the brain: a double-edged sword. J Mol Med. 2007;85:1351&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17594069</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson CM, Hale PT, Carlin JM. The role of IFN-&#x3b3; and TNF-&#x3b1;-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res. 2005;25:20&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1488823</ArticleId><ArticleId IdType="pubmed">15684619</ArticleId></ArticleIdList></Reference><Reference><Citation>Babcock TA, Carlin JM. Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor &#x3b1; in interferon-treated epithelial cells. Cytokine. 2000;12:588&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">10843733</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson CM, Shirey KA, Carlin JM. Synergistic transcriptional activation of indoleamine dioxygenase by IFN-&#x3b3; and tumor necrosis factor-&#x3b1;. J Interferon Cytokine Res. 2003;23:413&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1488822</ArticleId><ArticleId IdType="pubmed">13678429</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell BM, Charych E, Lee AW, M&#xf6;ller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci. 2014;8:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3915289</ArticleId><ArticleId IdType="pubmed">24567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Musso T, Gusella GL, Brooks A, Longo DL, Varesio L. Interleukin-4 inhibits indoleamine 2, 3-dioxygenase expression in human monocytes. Blood. 1994. 10.1182/blood.V83.5.1408.bloodjournal8351408.</Citation><ArticleIdList><ArticleId IdType="pubmed">8118042</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe1;l EM, Sherman AD. l-Kynurenine Its synthesis and possible regulatory function in brain. Neurochem Res. 1980;5:223&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">6154900</ArticleId></ArticleIdList></Reference><Reference><Citation>Badawy AA. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int j tryptophan res. 2017;10:1178646917691938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5398323</ArticleId><ArticleId IdType="pubmed">28469468</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxenkrug GF. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan&#x2014;kynurenine metabolism. Ann N Y Acad Sci. 2010;1199:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">20633104</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Gallausiaux C, Larraufie P, Jarry A, B&#xe9;guet-Crespel F, Marinelli L, Ledue F, Reimann F, Blotti&#xe8;re HM, Lapaque N. Butyrate produced by commensal bacteria down-regulates indolamine 2, 3-dioxygenase 1 (IDO-1) expression via a dual mechanism in human intestinal epithelial cells. Front Immunol. 2018;9:2838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6297836</ArticleId><ArticleId IdType="pubmed">30619249</ArticleId></ArticleIdList></Reference><Reference><Citation>Vujkovic-Cvijin I, Swainson LA, Chu SN, Ortiz AM, Santee CA, Petriello A, Dunham RM, Fadrosh DW, Lin DL, Faruqi AA. Gut-resident Lactobacillus abundance associates with IDO1 inhibition and Th17 dynamics in SIV-infected macaques. Cell Rep. 2015;13:1589&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4782968</ArticleId><ArticleId IdType="pubmed">26586432</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, Li T, Yin Y. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol. 2018;8:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5808205</ArticleId><ArticleId IdType="pubmed">29468141</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S. Short chain fatty acids and its producing organisms: an overlooked therapy for IBD? EBioMedicine. 2021. 10.1016/j.ebiom.2021.103293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8047503</ArticleId><ArticleId IdType="pubmed">33813134</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberati-Giani D, Ricciardi-Castagnoli P, K&#xf6;hler C, Cesura AM. Regulation of the kynurenine metabolic pathway by interferon-&#x3b3; in murine cloned macrophages and microglial cells. J Neurochem. 1996;66:996&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">8769859</ArticleId></ArticleIdList></Reference><Reference><Citation>Zunszain PA, Anacker C, Cattaneo A, Choudhury S, Musaelyan K, Myint AM, Thuret S, Price J, Pariante CM. Interleukin-1&#x3b2;: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology. 2012;37:939&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280640</ArticleId><ArticleId IdType="pubmed">22071871</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes AJ, Zheng X, O&#x2019;Kelly J, Neyton LP, Bochkina NA, Uings I, Liddle J, Baillie JK, Just G, Binnie M. Kynurenine monooxygenase regulates inflammation during critical illness and recovery in experimental acute pancreatitis. Cell Rep. 2023. 10.1016/j.celrep.2023.112763.</Citation><ArticleIdList><ArticleId IdType="pubmed">37478012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchinson JP, Rowland P, Taylor MR, Christodoulou EM, Haslam C, Hobbs CI, Holmes DS, Homes P, Liddle J, Mole DJ. Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. Nat Commun. 2017;8:15827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5477544</ArticleId><ArticleId IdType="pubmed">28604669</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddle J, Beaufils B, Binnie M, Bouillot A, Denis AA, Hann MM, Haslam CP, Holmes DS, Hutchinson JP, Kranz M. The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis. Bioorg Med Chem Lett. 2017;27:2023&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28336141</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgartner R, Berg M, Matic L, Polyzos K, Forteza M, Hjorth SA, Schwartz TW, Paulsson-Berne G, Hansson G, Hedin U. Evidence that a deviation in the kynurenine pathway aggravates atherosclerotic disease in humans. J Intern Med. 2021;289:53&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">32794238</ArticleId></ArticleIdList></Reference><Reference><Citation>Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O&#x2019;Mahony L, Palomares O. Interleukins, from 1 to 37, and interferon-&#x3b3;: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2011. 10.1016/j.jaci.2010.11.050.</Citation><ArticleIdList><ArticleId IdType="pubmed">21377040</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadimitriou C, Celikkaya H, Cosacak MI, Mashkaryan V, Bray L, Bhattarai P, Brandt K, Hollak H, Chen X, He S. 3D culture method for Alzheimer&#x2019;s disease modeling reveals interleukin-4 rescues A&#x3b2;42-induced loss of human neural stem cell plasticity. Dev cell. 2018. 10.1016/j.devcel.2018.06.005.</Citation><ArticleIdList><ArticleId IdType="pubmed">29974866</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherian AK, Gritton H, Johnson DE, Young D, Kozak R, Sarter M. A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats. Neuropharmacology. 2014;82:41&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4372264</ArticleId><ArticleId IdType="pubmed">24647121</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Ayala T, Sathyasaikumar K, Uys J, Perez-De-La-Cruz V, Pidugu L, Schwarcz R. N-acetylcysteine inhibits kynurenine aminotransferase II. Neuroscience. 2020;444:160&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484245</ArticleId><ArticleId IdType="pubmed">32768617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondanelli G, Iacono A, Carvalho A, Orabona C, Volpi C, Pallotta MT, Matino D, Esposito S, Grohmann U. Amino acid metabolism as drug target in autoimmune diseases. Autoimmun Rev. 2019;18:334&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">30797943</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe1;ndi Y, V&#xe9;csei L. The kynurenine system and immunoregulation. J Neural Transm. 2012;119:197&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">21744051</ArticleId></ArticleIdList></Reference><Reference><Citation>Harden JL, Egilmez NK. Indoleamine 2, 3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest. 2012;41:738&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3645912</ArticleId><ArticleId IdType="pubmed">23017144</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracho-Sanchez E, Hassanzadeh A, Brusko MA, Wallet MA, Keselowsky BG. Dendritic cells treated with exogenous indoleamine 2, 3-dioxygenase maintain an immature phenotype and suppress antigen-specific T cell proliferation. J immunol regen med. 2019;5: 100015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6884339</ArticleId><ArticleId IdType="pubmed">31788580</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallarino F, Vacca C, Orabona C, Belladonna ML, Bianchi R, Marshall B, Keskin DB, Mellor AL, Fioretti MC, Grohmann U. Functional expression of indoleamine 2, 3-dioxygenase by murine CD8&#x3b1;+ dendritic cells. Int Immunol. 2002;14:65&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11751753</ArticleId></ArticleIdList></Reference><Reference><Citation>Shortman K, Liu Y-J. Mouse and human dendritic cell subtypes. Nat Rev Immunol. 2002;2:151&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11913066</ArticleId></ArticleIdList></Reference><Reference><Citation>Reizis B. Plasmacytoid dendritic cells: development, regulation, and function. Immunity. 2019;50:37&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6342491</ArticleId><ArticleId IdType="pubmed">30650380</ArticleId></ArticleIdList></Reference><Reference><Citation>Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev. 2010;234:142&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507434</ArticleId><ArticleId IdType="pubmed">20193017</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853342</ArticleId><ArticleId IdType="pubmed">23516985</ArticleId></ArticleIdList></Reference><Reference><Citation>Sichien D, Lambrecht B, Guilliams M, Scott C. Development of conventional dendritic cells: from common bone marrow progenitors to multiple subsets in peripheral tissues. Mucosal Immunol. 2017;10:831&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">28198365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalantari T, Kamali-Sarvestani E, Ciric B, Karimi MH, Kalantari M, Faridar A, Xu H, Rostami A. Generation of immunogenic and tolerogenic clinical-grade dendritic cells. Immunol Res. 2011;51:153&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474330</ArticleId><ArticleId IdType="pubmed">22105838</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone TW, Williams RO. Modulation of T cells by tryptophan metabolites in the kynurenine pathway. Trends Pharmacol Sci. 2023. 10.1016/j.tips.2023.04.006.</Citation><ArticleIdList><ArticleId IdType="pubmed">37248103</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurado-Manzano BB, Zavala-Reyes D, Turrubiartes-Mart&#xed;nez EA, Portales-P&#xe9;rez DP, Gonz&#xe1;lez-Amaro R, Layseca-Espinosa E. FICZ generates human tDCs that induce CD4+ CD25high Foxp3+ treg-like cell differentiation. Immunol Lett. 2017;190:84&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">28765071</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor &#x3b6;-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176:6752&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">16709834</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008;8(5):337&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">18408735</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X-F, Wang H-S, Wang H, Zhang F, Wang K-F, Guo Q, Zhang G, Cai S-H, Du J. The role of indoleamine 2, 3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells. Cell Immunol. 2014;289:42&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24721110</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93:250&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Fara A, Mitrev Z, Rosalia RA, Assas BM. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biol. 2020;10: 200160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536084</ArticleId><ArticleId IdType="pubmed">32961074</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser DD, Slessarev M, Martin CM, Daley M, Patel MA, Miller MR, Patterson EK, O&#x2019;Gorman DB, Gill SE, Wishart DS. Metabolomics profiling of critically ill coronavirus disease 2019 patients: identification of diagnostic and prognostic biomarkers. Crit Care Explor. 2020. 10.1097/CCE.0000000000000272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7587450</ArticleId><ArticleId IdType="pubmed">33134953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lionetto L, Ulivieri M, Capi M, De Bernardini D, Fazio F, Petrucca A, Pomes LM, De Luca O, Gentile G, Casolla B. Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2021. 10.1016/j.bbadis.2020.166042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834629</ArticleId><ArticleId IdType="pubmed">33338598</ArticleId></ArticleIdList></Reference><Reference><Citation>Mar&#xed;n-Corral J, Rodr&#xed;guez-Morat&#xf3; J, Gomez-Gomez A, Pascual-Guardia S, Mu&#xf1;oz-Berm&#xfa;dez R, Salazar-Degracia A, P&#xe9;rez-Ter&#xe1;n P, Restrepo MI, Khymenets O, Haro N. Metabolic signatures associated with severity in hospitalized COVID-19 patients. Int J Mol Sci. 2021;22:4794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8124482</ArticleId><ArticleId IdType="pubmed">33946479</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Kim DJ, Takahashi T, Broadhurst DI, Yan H, Ma S, Rattray NJ, Casanovas-Massana A, Israelow B, Klein J. Kynurenic acid may underlie sex-specific immune responses to COVID-19. Sci Signal. 2021. 10.1126/scisignal.abf8483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8432948</ArticleId><ArticleId IdType="pubmed">34230210</ArticleId></ArticleIdList></Reference><Reference><Citation>Turski WA, Wnorowski A, Turski GN, Turski CA, Turski L. AhR and IDO1 in pathogenesis of Covid-19 and the &#x201c;Systemic AhR Activation Syndrome&#x201d; translational review and therapeutic perspectives. Restor Neurol Neurosci. 2020. 10.3233/RNN-201042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7592680</ArticleId><ArticleId IdType="pubmed">32597823</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe MM, Mold JE, Kanwar B, Huang Y, Louie A, Pollastri MP, Wang C, Patel G, Franks DG, Schlezinger J. Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production. PLoS ONE. 2014;9: e87877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912126</ArticleId><ArticleId IdType="pubmed">24498387</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010;84:12658&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3004351</ArticleId><ArticleId IdType="pubmed">20926566</ArticleId></ArticleIdList></Reference><Reference><Citation>Sariol A, Perlman S. SARS-CoV-2 takes its Toll. Nat Immunol. 2021;22:801&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238877</ArticleId><ArticleId IdType="pubmed">34103714</ArticleId></ArticleIdList></Reference><Reference><Citation>Manik M, Singh RK. Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19. J Med Virol. 2022;94:869&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662021</ArticleId><ArticleId IdType="pubmed">34672376</ArticleId></ArticleIdList></Reference><Reference><Citation>Larigot L, Juricek L, Dairou J, Coumoul X. AhR signaling pathways and regulatory functions. Biochimie Open. 2018;7:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039966</ArticleId><ArticleId IdType="pubmed">30003042</ArticleId></ArticleIdList></Reference><Reference><Citation>Neavin DR, Liu D, Ray B, Weinshilboum RM. The role of the aryl hydrocarbon receptor (AHR) in immune and inflammatory diseases. Int J Mol Sci. 2018. 10.3390/ijms19123851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6321643</ArticleId><ArticleId IdType="pubmed">30513921</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Niu Y, Luo P, Xiao F, Yuan F, Yin H, Chen S, Guo F. Amino acid sensor GCN2 promotes SARS-CoV-2 receptor ACE2 expression in response to amino acid deprivation. Commun Biol. 2022;5:651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9249868</ArticleId><ArticleId IdType="pubmed">35778545</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie X, Qian L, Sun R, Huang B, Dong X, Xiao Q, Zhang Q, Lu T, Yue L, Chen S. Multi-organ proteomic landscape of COVID-19 autopsies. Cell. 2021;184:775&#x2013;91. 10.1016/j.cell.2021.01.004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7794601</ArticleId><ArticleId IdType="pubmed">33503446</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunewald ME, Shaban MG, Mackin SR, Fehr AR, Perlman S. Murine coronavirus infection activates the aryl hydrocarbon receptor in an indoleamine 2, 3-dioxygenase-independent manner, contributing to cytokine modulation and proviral TCDD-inducible-PARP expression. J Virol. 2020. 10.1128/JVI.01743-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7000979</ArticleId><ArticleId IdType="pubmed">31694960</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116:1097&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184507</ArticleId><ArticleId IdType="pubmed">32227090</ArticleId></ArticleIdList></Reference><Reference><Citation>Turski WA, Wnorowski A, Turski GN, Turski CA, Turski L. AhR and IDO1 in pathogenesis of Covid-19 and the &#x201c;Systemic AhR Activation Syndrome:&#x201d; a translational review and therapeutic perspectives. Restor Neurol Neurosci. 2020;38:343&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7592680</ArticleId><ArticleId IdType="pubmed">32597823</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus. Treasure Island (FL): StatPearls Publishing; 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">32150360</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kr&#xfc;ger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, M&#xfc;ller MA, Drosten C, P&#xf6;hlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>McGavern DB, Kang SS. Illuminating viral infections in the nervous system. Nat Rev Immunol. 2011;11:318&#x2013;29. 10.1038/nri2971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5001841</ArticleId><ArticleId IdType="pubmed">21508982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M-H, Perl DP, Nair G, Li W, Maric D, Murray H, Dodd SJ, Koretsky AP, Watts JA, Cheung V. Microvascular injury in the brains of patients with Covid-19. N Engl J Med. 2021;384:481&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787217</ArticleId><ArticleId IdType="pubmed">33378608</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J, L&#xfc;tgehetmann M, Hagel C, Sperhake JP, Schr&#xf6;der AS, Edler C, Mushumba H, Fitzek A, Allweiss L, Dandri M. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. The Lancet Neurology. 2020;19:919&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, Chung J-Y, Singh M, Yinda CK, Winkler CW, Sun J, Dickey JM, Ylaya K. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Crunfli F, Carregari VC, Veras FP, Silva LS, Nogueira MH, Antunes ASLM, Vendramini PH, Valen&#xe7;a AGF, Brand&#xe3;o-Teles C, Zuccoli GdS. Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc Natl Acad Sci. 2022;119: e2200960119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9436354</ArticleId><ArticleId IdType="pubmed">35951647</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO (2022) Post COVID-19 condition (Long COVID). https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition. 2023</Citation></Reference><Reference><Citation>(CDC) CfDCaP (2023) Long COVID or Post-COVID Conditions. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.</Citation></Reference><Reference><Citation>Holmes E, Wist J, Masuda R, Lodge S, Nitschke P, Kimhofer T, Loo RL, Begum S, Boughton B, Yang R. Incomplete systemic recovery and metabolic phenoreversion in Post-Acute-Phase nonhospitalized COVID-19 patients: implications for assessment of Post-Acute COVID-19 syndrome. J Proteome Res. 2021. 10.1021/acs.jproteome.1c00224.</Citation><ArticleIdList><ArticleId IdType="pubmed">34009992</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mul&#xe8; G, Augello M, Mondatore D, Allegrini M, Cona A. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. 2022;28:611. 10.1016/j.cmi.2021.11.002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Mart&#xed;n-Guerrero JD, Pellicer-Valero &#xd3;J, Navarro-Pardo E, G&#xf3;mez-Mayordomo V, Cuadrado ML, Arias-Naval&#xf3;n JA, Cigar&#xe1;n-M&#xe9;ndez M, Hern&#xe1;ndez-Barrera V, Arendt-Nielsen L. Female sex is a risk factor associated with long-term post-COVID related-symptoms but not with COVID-19 symptoms: the LONG-COVID-EXP-CM multicenter study. J Clin Med. 2022. 10.3390/jcm11020413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8778106</ArticleId><ArticleId IdType="pubmed">35054108</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, Elneima O, Docherty AB, Lone NI, Leavy OC. Physical cognitive and mental health impacts of COVID 19 following hospitalisation a multi centre prospective cohort study. medRxiv. 2021. 10.1016/S2213-2600(21)00383-0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Darley DR, Dore GJ, Cysique L, Wilhelm KA, Andresen D, Tonga K, Stone E, Byrne A, Plit M, Masters J. Persistent symptoms up to four months after community and hospital-managed SARS-CoV-2 infection. Med J Aust. 2021;214:279&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014234</ArticleId><ArticleId IdType="pubmed">33657671</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewthwaite H, Byrne A, Brew B, Gibson PG. Treatable traits for long COVID. Respirol. 2023;28:1005&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">37715729</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Gennaro F, Belati A, Tulone O, Diella L, Fiore Bavaro D, Bonica R, Genna V, Smith L, Trott M, Bruyere O. Incidence of long COVID-19 in people with previous SARS-Cov2 infection: A systematic review and meta-analysis of 120,970 patients. Intern Emerg Med. 2023;18:1573&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9709360</ArticleId><ArticleId IdType="pubmed">36449260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung TJ, Neumann C, Bahmer T, Chaplinskaya-Sobol I, Endres M, Geritz J, Haeusler KG, Heuschmann PU, Hildesheim H, Hinz A. Fatigue and cognitive impairment after COVID-19: a prospective multicentre study. EClinicalMed. 2022. 10.1016/j.eclinm.2022.101651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9482331</ArticleId><ArticleId IdType="pubmed">36133318</ArticleId></ArticleIdList></Reference><Reference><Citation>Tana C, Bentivegna E, Cho S-J, Harriott AM, Garc&#xed;a-Azor&#xed;n D, Labastida-Ramirez A, Ornello R, Raffaelli B, Beltr&#xe1;n ER, Ruscheweyh R. Long COVID headache. J Headache Pain. 2022;23:93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9340759</ArticleId><ArticleId IdType="pubmed">35915417</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Dab&#xf3; L, Melgarejo-Mart&#xed;nez L, Caronna E, Pozo-Rosich P. Headache in COVID-19 and long COVID: to Know facts for clinical practice. Curr Neurol Neurosci Rep. 2023;23:551&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">37665495</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues AN, Dias ARN, Paranhos ACM, Silva CC, Bastos TdR, Brito BBd, da Silva NM, de Sousa EdJS, Quaresma JAS, Falc&#xe3;o LFM. Headache in long COVID as disabling condition: a clinical approach. Front Neurol. 2023;14:1149294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10076861</ArticleId><ArticleId IdType="pubmed">37034080</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Navarro-Santana M, G&#xf3;mez-Mayordomo V, Cuadrado ML, Garc&#xed;a-Azor&#xed;n D, Arendt-Nielsen L, Plaza-Manzano G. Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: a meta-analysis of the current literature. Eur J Neurol. 2021;28:3820&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8444899</ArticleId><ArticleId IdType="pubmed">34327787</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Azorin D, Layos-Romero A, Porta-Etessam J, Membrilla JA, Caronna E, Gonzalez-Martinez A, Mencia &#xc1;S, Segura T, Gonzalez-Garc&#xed;a N, D&#xed;az-de-Ter&#xe1;n J. Post-COVID-19 persistent headache: a multicentric 9-months follow-up study of 905 patients. Cephalalgia. 2022;42:804&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">35166156</ArticleId></ArticleIdList></Reference><Reference><Citation>Tana C, Giamberardino MA, Martelletti P. Long COVID and especially headache syndromes. Curr Opin Neurol. 2023;36:168&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">37078648</ArticleId></ArticleIdList></Reference><Reference><Citation>Spekker E, Nagy-Gr&#xf3;cz G, V&#xe9;csei L. Ion channel disturbances in migraine headache: exploring the potential role of the Kynurenine System in the context of the trigeminovascular system. Int J Mol Sci. 2023;24:16574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10706278</ArticleId><ArticleId IdType="pubmed">38068897</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y-J, Li Y-L, Fang Z-H, Liao H-L, Zhang Y-Y, Lin J, Liu F, Shen J-F. NMDARs mediate peripheral and central sensitization contributing to chronic orofacial pain. Front Cell Neurosci. 2022;16: 999509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9553029</ArticleId><ArticleId IdType="pubmed">36238833</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. J Clin Neurol. 2012;8:89&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391624</ArticleId><ArticleId IdType="pubmed">22787491</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Suzuki S, Shiina T, Kobayashi S, Hirata K. Central sensitization in migraine: a narrative review. J Pain Res. 2022. 10.2147/JPR.S329280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9464439</ArticleId><ArticleId IdType="pubmed">36101891</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone TW, Mackay GM, Forrest CM, Clark CJ, Darlington LG. Tryptophan metabolites and brain disorders. Clin Chem Lab Med. 2003. 10.1515/CCLM.2003.129.</Citation><ArticleIdList><ArticleId IdType="pubmed">12940508</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V, Takikawa O, Brew BJ. Characterization of the kynurenine pathway in human neurons. J Neurosci. 2007;27:12884&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673280</ArticleId><ArticleId IdType="pubmed">18032661</ArticleId></ArticleIdList></Reference><Reference><Citation>Curto M, Lionetto L, Negro A, Capi M, Fazio F, Giamberardino MA, Simmaco M, Nicoletti F, Martelletti P. Altered kynurenine pathway metabolites in serum of chronic migraine patients. J Headache Pain. 2016;17:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4851673</ArticleId><ArticleId IdType="pubmed">27130315</ArticleId></ArticleIdList></Reference><Reference><Citation>Urenjak J, Obrenovitch TP. Kynurenine 3-hydroxylase inhibition in rats: effects on extracellular kynurenic acid concentration and N-methyl-D-aspartate-induced depolarisation in the striatum. J Neurochem. 2000;75:2427&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">11080194</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendtsen L. Central sensitization in tension-type headache&#x2014;possible pathophysiological mechanisms. Cephalalgia. 2000;20:486&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">11037746</ArticleId></ArticleIdList></Reference><Reference><Citation>Velling DA, Dodick DW, Muir JJ. Sustained-release niacin for prevention of migraine headache. Mayo Clin Proc. 2003. 10.4065/78.6.770.</Citation><ArticleIdList><ArticleId IdType="pubmed">12934790</ArticleId></ArticleIdList></Reference><Reference><Citation>Loewendorf AI, Matynia A, Saribekyan H, Gross N, Csete M, Harrington M. Roads less traveled: sexual dimorphism and mast cell contributions to migraine pathology. Front Immunol. 2016;7: 170131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836167</ArticleId><ArticleId IdType="pubmed">27148260</ArticleId></ArticleIdList></Reference><Reference><Citation>Smitherman TA, Walters AB, Maizels M, Penzien DB. The use of antidepressants for headache prophylaxis. CNS Neurosci Ther. 2011;17:462&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6493799</ArticleId><ArticleId IdType="pubmed">21951370</ArticleId></ArticleIdList></Reference><Reference><Citation>Loder EW. Menstrual migraine: pathophysiology, diagnosis, and impact. Headache. 2006. 10.1111/j.1526-4610.2006.00555.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">17044842</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobler C, Maphumulo SC, Grobbelaar LM, Bredenkamp JC, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB, Pretorius E. Covid-19: the rollercoaster of fibrin (ogen), d-dimer, von willebrand factor, p-selectin and their interactions with endothelial cells, platelets and erythrocytes. Int J Mol Sci. 2020;21:5168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7403995</ArticleId><ArticleId IdType="pubmed">32708334</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematology. 2020;7:e438&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7213964</ArticleId><ArticleId IdType="pubmed">32407672</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, Kell DB. Persistent clotting protein pathology in Long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar LM, Venter C, Vlok M, Ngoepe M, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB, Pretorius E. SARS-CoV-2 spike protein S1 induces fibrin (ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. 2021. Biosci Rep. 10.1042/BSR20210611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380922</ArticleId><ArticleId IdType="pubmed">34328172</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J. 2022;479:537&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger A, Vlok M, Turner S, Venter C, Laubscher GJ, Kell DB, Pretorius E. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol. 2022;21:1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="pubmed">36131342</ArticleId></ArticleIdList></Reference><Reference><Citation>Voils SA, Shahin MH, Garrett TJ, Frye RF. Metabolomic association between venous thromboembolism in critically ill trauma patients and kynurenine pathway of tryptophan metabolism. Thromb Res. 2018;165:6&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">29544199</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlak K, Mysliwiec M, Pawlak D. Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients. Thromb Haemost. 2009;102:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">19572067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mor A, Kalaska B, Pawlak D. Kynurenine pathway in chronic kidney disease: what&#x2019;s old, what&#x2019;s new, and what&#x2019;s next? Int J Tryptophan Res. 2020;13:1178646920954882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862190</ArticleId><ArticleId IdType="pubmed">35210786</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci. 2017;20:145&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6960010</ArticleId><ArticleId IdType="pubmed">28092661</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvo-Romero E, Stokes P, Gareau MG. Microbiota-immune interactions: from gut to brain. LymphoSign J. 2020;7:1&#x2013;23.</Citation></Reference><Reference><Citation>Lee J, Venna VR, Durgan DJ, Shi H, Hudobenko J, Putluri N, Petrosino J, McCullough LD, Bryan RM. Young versus aged microbiota transplants to germ-free mice: increased short-chain fatty acids and improved cognitive performance. Gut microbes. 2020;12:1814107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7757789</ArticleId><ArticleId IdType="pubmed">32897773</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Zhou Y, Ma Y, Chen P, Tang J, Yang B, Li H, Liang M, Xue Y, Liu Y. Gut microbiota dysbiosis correlates with long COVID-19 at one-year after discharge. J Korean Med Sci. 2023. 10.3346/jkms.2023.38.e120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10111044</ArticleId><ArticleId IdType="pubmed">37069814</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony SM, Clarke G, Borre Y, Dinan TG, Cryan J. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res. 2015;277:32&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">25078296</ArticleId></ArticleIdList></Reference><Reference><Citation>Savitz J. The kynurenine pathway: a finger in every pie. Mol Psychiatry. 2020;25:131&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6790159</ArticleId><ArticleId IdType="pubmed">30980044</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin DE. Why does viral RNA sometimes persist after recovery from acute infections? PLoS Biol. 2022;20: e3001687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9191737</ArticleId><ArticleId IdType="pubmed">35648781</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JC, Muecksch F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, Walt DR. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76:e487&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceulemans LJ, Khan M, Yoo S-J, Zapiec B, Van Gerven L, Van Slambrouck J, Vanstapel A, Van Raemdonck D, Vos R, Wauters E. Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19. Lancet Respir Med. 2021;9:e78&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8189667</ArticleId><ArticleId IdType="pubmed">34118186</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Francisco EB, Yogendra R, Long E, Pise A, Rodrigues H, Hall E, Herrera M, Parikh P, Guevara-Coto J. Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front Immunol. 2022;12:5526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Zadeh FH, Wilson DR, Agrawal DK. Long COVID: complications, underlying mechanisms, and treatment strategies. Arch Microbiol Immunol. 2023;7:36&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10310313</ArticleId><ArticleId IdType="pubmed">37388279</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal KDE, Whitehurst CB. Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients. Virus Res. 2023;334: 199157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10292739</ArticleId><ArticleId IdType="pubmed">37364815</ArticleId></ArticleIdList></Reference><Reference><Citation>Manoharan S, Ying LY. Epstein Barr virus reactivation during COVID-19 hospitalization significantly increased mortality/death in SARS-CoV-2 (+)/EBV (+) than SARS-CoV-2 (+)/EBV (&#x2212;) Patients: a comparative meta-analysis. Int J Clinic Pract. 2023. 10.1155/2023/1068000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9904914</ArticleId><ArticleId IdType="pubmed">36793928</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: the role of Epstein-Barr virus and the gut&#x2013;brain axis. Mol Psychiatr. 2023;28:4968&#x2013;76. 10.1038/s41380-023-02161-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11041741</ArticleId><ArticleId IdType="pubmed">37402856</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10:763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, Tabachnikova A, Greene K, Tabacof L, Malik AA. Distinguishing features of Long COVID identified through immune profiling. Nature. 2023;623:139&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W-l, Lin Y-h, Xiao H, Xing S, Chen H, Chi P-d, Zhang G. Epstein-Barr virus infection induces indoleamine 2, 3-dioxygenase expression in human monocyte-derived macrophages through p38/mitogen-activated protein kinase and NF-&#x3ba;B pathways: impairment in T cell functions. J Virol. 2014;88:6660&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4054364</ArticleId><ArticleId IdType="pubmed">24696473</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EMT, Furlan R, Ciceri F, Rovere-Querini P. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390748</ArticleId><ArticleId IdType="pubmed">32738287</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamoorthy Y, Nagarajan R, Saya GK, Menon V. Prevalence of psychological morbidities among general population, healthcare workers and COVID-19 patients amidst the COVID-19 pandemic: a systematic review and meta-analysis. Psychiatry Res. 2020;293: 113382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7417292</ArticleId><ArticleId IdType="pubmed">32829073</ArticleId></ArticleIdList></Reference><Reference><Citation>Naidu SB, Shah AJ, Saigal A, Smith C, Brill SE, Goldring J, Hurst JR, Jarvis H, Lipman M, Mandal S. The high mental health burden of &#x201c;Long COVID&#x201d; and its association with on-going physical and respiratory symptoms in all adults discharged from hospital. Eur Respir J. 2021;57:2004364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8015645</ArticleId><ArticleId IdType="pubmed">33795319</ArticleId></ArticleIdList></Reference><Reference><Citation>Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Int J Biochem Cell Biol. 2002;13:455&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">12401480</ArticleId></ArticleIdList></Reference><Reference><Citation>Essa MM, Hamdan H, Chidambaram SB, Al-Balushi B, Guillemin GJ, Ojcius DM, Qoronfleh MW. Possible role of tryptophan and melatonin in COVID-19. Int J Tryptophan Res. 2020;13:1178646920951832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7443751</ArticleId><ArticleId IdType="pubmed">32913393</ArticleId></ArticleIdList></Reference><Reference><Citation>Marciniak E, Faivre E, Dutar P, Pires CA, Demeyer D, Caillierez R, Laloux C, Bu&#xe9;e L, Blum D, Humez S. The Chemokine MIP-1&#x3b1;/CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory. Sci Rep. 2015;5:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4625372</ArticleId><ArticleId IdType="pubmed">26511387</ArticleId></ArticleIdList></Reference><Reference><Citation>Sforzini L, Nettis MA, Mondelli V, Pariante CM. Inflammation in cancer and depression: a starring role for the kynurenine pathway. Psychopharmacology. 2019;236:2997&#x2013;3011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6820591</ArticleId><ArticleId IdType="pubmed">30806743</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Cai H, Chen L, Liang D, Yang R, Dang R, Jiang P. Quantitative profiling of neurotransmitter abnormalities in the hippocampus of rats treated with lipopolysaccharide: focusing on kynurenine pathway and implications for depression. J Neuroimmunol. 2016;295:41&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27235347</ArticleId></ArticleIdList></Reference><Reference><Citation>Serafini G, Adavastro G, Canepa G, Capobianco L, Conigliaro C, Pittaluga F, Belvederi Murri M, Valchera A, De Berardis D, Pompili M. Abnormalities in kynurenine pathway metabolism in treatment-resistant depression and suicidality: a systematic review. CNS Neurol Disord Drug Targets. 2017;16:440&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">28412922</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroon E, Welle JR, Woolwine BJ, Goldsmith DR, Baer W, Patel T, Felger JC, Miller AH. Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. Neuropsychopharmacol. 2020;45:998&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7162907</ArticleId><ArticleId IdType="pubmed">31940661</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein H-G, Sarnyai Z, Mawrin C, Brisch R, Bielau H, zu Schwabedissen LM,. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation. 2011;8:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177898</ArticleId><ArticleId IdType="pubmed">21831269</ArticleId></ArticleIdList></Reference><Reference><Citation>Savitz J, Ford BN, Yeh H-W, Akeman E, Cosgrove K, Clausen AN, Martell C, Kirlic N, Santiago J, Teague TK. Behavioral activation therapy for depression is associated with a reduction in the concentration of circulating quinolinic acid. Psychol Med. 2020;52:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8144244</ArticleId><ArticleId IdType="pubmed">33234171</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantzer R, O&#x2019;connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919277</ArticleId><ArticleId IdType="pubmed">18073775</ArticleId></ArticleIdList></Reference><Reference><Citation>Myint A-M, Kim YK, Verkerk R, Scharp&#xe9; S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007;98:143&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">16952400</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Hollern D, Liao J, Andrechek E, Wang H. NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death Dis. 2013;4:e560&#x2013;e560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615746</ArticleId><ArticleId IdType="pubmed">23538441</ArticleId></ArticleIdList></Reference><Reference><Citation>Vav&#xe1;kov&#xe1; M, &#x10e;ura&#x10d;kov&#xe1; Z, Trebatick&#xe1; J. Markers of oxidative stress and neuroprogression in depression disorder. Oxid Med Cell Longev. 2015;2015: 898393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4453280</ArticleId><ArticleId IdType="pubmed">26078821</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz NAL, Del &#xc1;ngel DS, Olgu&#xed;n HJ, Silva ML. Neuroprogression: the hidden mechanism of depression. Neuropsychiatr Dis Treat. 2018;14:2837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6214587</ArticleId><ArticleId IdType="pubmed">30464468</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, Rose EB, Shapiro NI, Files DC, Gibbs KW, Erickson HL, Steingrub JS, Smithline HA. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network&#x2014;United States, March&#x2013;June 2020. Morb Mortal Wkly Rep. 2020;69:993&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, O&#x2019;Connor L, Leavy D, O&#x2019;Brien K, Dowds J. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS ONE. 2020;15: e0240784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL. The Tragedy of the Post-COVID &#x201c;Long Haulers.&#x201d; Harvard Health Letter: Harvard Health Publishng, Harvard Medical School; 2021.</Citation></Reference><Reference><Citation>Bornstein SR, Voit-Bak K, Donate T, Rodionov RN, Gainetdinov RR, Tselmin S, Kanczkowski W, M&#xfc;ller GM, Achleitner M, Wang J. Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis? Mol Psychiatry. 2021;27:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8209771</ArticleId><ArticleId IdType="pubmed">34140635</ArticleId></ArticleIdList></Reference><Reference><Citation>Dibble JJ, McGrath SJ, Ponting CP. Genetic risk factors of ME/CFS: a critical review. Hum Mol Genet. 2020;29:R117&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7530519</ArticleId><ArticleId IdType="pubmed">32744306</ArticleId></ArticleIdList></Reference><Reference><Citation>Mona Dehhaghi HKSP, Kavyani B, Heng B, Tan V, Braidy N, Guillemin GJ. The role of Kynurenine pathway and NAD + metabolism in myalgic Encephalomyelitis/Chronic fatigue syndrome. Aging Dis. 2022;13:698&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9116917</ArticleId><ArticleId IdType="pubmed">35656104</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoun Sebaiti M, Hainselin M, Gounden Y, Sirbu CA, Sekulic S, Lorusso L, Nacul L, Authier FJ. Systematic review and meta-analysis of cognitive impairment in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Sci Rep. 2022;12:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8828740</ArticleId><ArticleId IdType="pubmed">35140252</ArticleId></ArticleIdList></Reference><Reference><Citation>McGregor NR, Armstrong CW, Lewis DP, Gooley PR. Post-exertional malaise is associated with hypermetabolism, hypoacetylation and purine metabolism deregulation in ME/CFS cases. Diagnostics. 2019;9:70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6787670</ArticleId><ArticleId IdType="pubmed">31277442</ArticleId></ArticleIdList></Reference><Reference><Citation>Braidy N, Guillemin GJ, Grant R. Effects of kynurenine pathway inhibition on NAD+ metabolism and cell viability in human primary astrocytes and neurons. Int J Tryptophan Res. 2011. 10.4137/IJTR.S7052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3195218</ArticleId><ArticleId IdType="pubmed">22084601</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffett JR, Arun P, Puthillathu N, Vengilote R, Ives JA, Badawy AA, Namboodiri AM. Quinolinate as a marker for kynurenine metabolite formation and the unresolved question of NAD+ synthesis during inflammation and infection. Front Immunol. 2020. 10.3389/fimmu.2020.00031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7047773</ArticleId><ArticleId IdType="pubmed">32153556</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber V, Am&#xe9; J-C, Doll&#xe9; P, Schultz I, Rinaldi B, Fraulob V, M&#xe9;nissier-de Murcia J, de Murcia G. Poly (ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem. 2002;277:23028&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11948190</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash S, Dash C, Pandhare J. Therapeutic significance of microRNA-mediated regulation of PARP-1 in SARS-CoV-2 infection. Noncoding RNA. 2021;7:60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8544662</ArticleId><ArticleId IdType="pubmed">34698261</ArticleId></ArticleIdList></Reference><Reference><Citation>Escarcega RD, Honarpisheh P, Colpo GD, Ahnstedt HW, Couture L, Juneja S, Torres G, Ortiz GJ, Sollome J, Tabor N. Sex differences in global metabolomic profiles of COVID-19 patients. Cell Death Dis. 2022;13:461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9106988</ArticleId><ArticleId IdType="pubmed">35568706</ArticleId></ArticleIdList></Reference><Reference><Citation>Danlos F-X, Grajeda-Iglesias C, Durand S, Sauvat A, Roumier M, Cantin D, Colomba E, Rohmer J, Pommeret F, Baciarello G. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death Dis. 2021;12:258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7948172</ArticleId><ArticleId IdType="pubmed">33707411</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangge H, Herrmann M, Meinitzer A, Pailer S, Curcic P, Sloup Z, Holter M, Pr&#xfc;ller F. Increased kynurenine indicates a fatal course of COVID-19. Antioxidants. 2021;10:1960. 10.3390/antiox10121960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8750518</ArticleId><ArticleId IdType="pubmed">34943063</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizjak DA, Stangl M, B&#xf6;rner N, B&#xf6;sch F, Durner J, Drunin G, Buhl J-L, Abendroth D. Kynurenine serves as useful biomarker in acute, long-and post-COVID-19 diagnostics. Front Immunol. 2022;13:1004545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537769</ArticleId><ArticleId IdType="pubmed">36211365</ArticleId></ArticleIdList></Reference><Reference><Citation>Cihan M, Do&#x11f;an &#xd6;, Ceran Serdar C, Altun&#xe7;eki&#xe7; Y&#x131;ld&#x131;r&#x131;m A, Kurt C, Serdar MA. Kynurenine pathway in coronavirus disease (COVID-19): potential role in prognosis. J Clin Lab Anal. 2022;36: e24257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8906035</ArticleId><ArticleId IdType="pubmed">35092710</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>